US FDA warns high-dose Diflucan linked to birth defects
This article was originally published in Scrip
Based on several published case reports, the US FDA on 3 August warned that chronic, high doses of 400-800mg/day of Pfizer's Diflucan (fluconazole) may be associated with a rare and distinct set of congenital anomalies in infants whose mothers were treated with the drug for serious and life-threatening fungal infections during the first trimester of pregnancy.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.